title: A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.
abstract: BACKGROUND
  There are few data directly comparing the effects of two-hour postingestion monitored cyclosporine (C2-CsA) vs. trough-monitored tacrolimus (C0-Tac) on renal function and cardiovascular risk factors.
  
  
  METHODS
  We studied 378 (202 C2-CsA vs. 176 C0-Tac) incident kidney transplant recipients in Toronto, Canada, from August 1, 2000 and December 31, 2003. Outcomes included changes in estimated glomerular filtration rate (eGFR at 1 and 6 months by modification of diet in renal disease four-variable equation), mean arterial pressure (MAP), total cholesterol (TC), and new-onset diabetes mellitus (NODM) at six months posttransplant. The independent effect of treatment/monitoring strategies on continuous outcomes and time-to-NODM was modeled using linear and Cox regression, respectively.
  
  
  RESULTS
  Mean eGFR was 59.5 vs. 62.9 ml/min at one month and 50.6 vs. 61.2 ml/min at six months for C2-CsA vs. C0-Tac, respectively. Multiple linear regression revealed the slope of eGFR to be 0.93 ml/min/month lower in C2-CsA patients. This was equivalent to an adjusted average eGFR difference of 4.64 ml/min between months one and six posttransplant. There was no significant difference in average MAP and TC. In a stepwise multivariable Cox model and a propensity score analysis, there was no significant association between the type of treatment/monitoring strategy and time-to-NODM.
  
  
  CONCLUSIONS
  There was a greater decline in eGFR for patients on C2-CsA (vs. C0-Tac) between one and six months posttransplant. However, MAP, TC, and the risk of NODM were comparable in both treatment/monitoring groups. The long-term impact of short-term reductions in eGFR as a function of the type of treatment/monitoring strategy requires further study.
authors.affiliation: Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: S Joseph
authors.initials: SJ
authors.lastname: Kim
authors.forename: G V Ramesh
authors.initials: GV
authors.lastname: Prasad
authors.forename: Michael
authors.initials: M
authors.lastname: Huang
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Nash
authors.forename: Olusegun
authors.initials: O
authors.lastname: Famure
authors.forename: Joseph
authors.initials: J
authors.lastname: Park
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Thenganatt
authors.forename: Nizamuddin
authors.initials: N
authors.lastname: Chowdhury
authors.forename: Edward H
authors.initials: EH
authors.lastname: Cole
authors.forename: Stanley S A
authors.initials: SS
authors.lastname: Fenton
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Cattran
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Zaltzman
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Cardella
mesh_terms: D000293:Adolescent; D000328:Adult; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D018579:Patient Selection; D011183:Postoperative Complications / Q000453:epidemiology; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus